In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature

Amino Acids

Volumn 46, Issue 12, 2014, Pages 2721-2732

  Ma, Wenhui ^a,b   Li, Guoquan ^a,b   Wang, Jing ^b   Yang, Weidong ^b   Zhang, Yingqi ^c   Conti, Peter S ^a   Chen, Kai ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD13 receptor; NGR; NIRF imaging; Tumor vasculature; Vascular endothelial growth inhibitor

Indexed keywords

ASPARAGINYLGLYCYLARGININE VASCULAR ENDOTHELIAL GROWTH INHIBITOR FUSION PROTEIN; CYANINE DYE; CYANINE DYE 5.5; HYBRID PROTEIN; UNCLASSIFIED DRUG; CARBOCYANINE; CY5.5 CYANINE DYE; FLUORESCENT DYE; MOLECULAR PROBE; NGR PEPTIDE; OLIGOPEPTIDE; TNFSF15 PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER THERAPY; CHEMICAL LABELING; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; FEMALE; FIBROSARCOMA; FIBROSARCOMA CELL LINE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING; HT 1080 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; PROKARYOTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR TO MUSCLE RATIO; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; EVALUATION STUDY; GENETICS; METABOLISM; NEAR INFRARED SPECTROSCOPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

PROKARYOTA;

ANIMALS; APOPTOSIS; CARBOCYANINES; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT DYES; HUMANS; MICE; MICE, NUDE; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; SPECTROSCOPY, NEAR-INFRARED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84919913741     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1828-6     Document Type: Article

References (60)

1. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R (2000) Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 35(8):479-485
2. Achilefu S, Jimenez HN, Dorshow RB, Bugaj JE, Webb EG, Wilhelm RR, Rajagopalan R, Johler J, Erion JL (2002) Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J Med Chem 45(10):2003-2015
3. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211-217
4. Bamias G, Martin C III, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F (2003) Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171(9):4868-4874
5. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97(3):652-659
6. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932-936
7. Chen K, Chen X (2010) Design and development of molecular imaging probes. Curr Top Med Chem 10(12):1227-1236
8. Chen K, Chen X (2011) Positron emission tomography imaging of cancer biology: current status and future prospects. Semi Oncol 38(1):70-86
9. Chen K, Conti PS (2010) Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 62(11):1005-1022
10. 3 in brain tumor xenografts. Cancer Res 64(21):8009-8014
11. 18F-labeled dimeric RGD peptide. Mol Imaging 3(2):96-104
12. Chen X, Wu J, Liu H, He Z, Gu M, Wang N, Ma J, Hu J, Xia L, He H, Yuan J, Li J, Li L, Li M, Zhu X (2010) Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci 19(3):449-457
13. Chen K, Yap LP, Park R, Hui X, Wu K, Fan D, Chen X, Conti PS (2012) A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. Amino Acids 42(4):1329-1337
14. 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol Pharm 10(1):417-427
15. 3 expression in living mice. Bioconjugate Chem 16(6):1433-1441
16. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16(7):742-744
17. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867
18. 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 38(1):128-137
19. Duan L, Yang G, Zhang R, Feng L, Xu C (2012) Advancement in the research on vascular endothelial growth inhibitor (VEGI). Target Oncol 7(1):87-90
20. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
21. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18
22. Goncalves M, Estieu-Gionnet K, Berthelot T, Lain G, Bayle M, Canron X, Betz N, Bikfalvi A, Deleris G (2005) Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions. Pharm Res 22(8):1411-1421
23. Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, Koivunen E, Sidman RL, Arap W, Pasqualini R (2012) Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA 109(5):1637-1642
24. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364
25. Haridas V, Shrivastava A, Su J, Yu GL, Ni J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R, Aggarwal BB (1999) VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18(47):6496-6504
26. Hou W, Medynski D, Wu S, Lin X, Li LY (2005) VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11(15):5595-5602
27. Jacobson O, Zhu L, Ma Y, Weiss ID, Sun X, Niu G, Kiesewetter DO, Chen X (2011) Rapid and simple one-step F-18 labeling of peptides. Bioconjugate Chem 22(3):422-428
28. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C (2003) Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 63(22):7870-7875
29. Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjugate Chem 22(10):1879-1903
30. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y (2010) New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev 110(5):2620-2640
31. Li G, Xing Y, Wang J, Conti PS, Chen K (2014) Near-infrared fluorescence imaging of CD13 receptor expression using a novel Cy5.5-labeled dimeric NGR peptide. Amino Acids 46(6):1547-1556
32. Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nature Rev Cancer 7(10):800-808
33. Mahmood U, Weissleder R (2003) Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2(5):489-496
34. Meng J, Yan Z, Wu J, Li L, Xue X, Li M, Li W, Hao Q, Wan Y, Qin X, Zhang C, You Y, Han W, Zhang Y (2007) High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a. Cytotherapy 9(1):60-68
35. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16(3):479-492
36. Moore A, Medarova Z, Potthast A, Dai G (2004) In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 64(5):1821-1827
37. Parr C, Gan CH, Watkins G, Jiang WG (2006) Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9(2):73-81
38. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60(3):722-727
39. Paudyal B, Paudyal P, Shah D, Tominaga H, Tsushima Y, Endo K (2014) Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. J Biomed Sci 21:35
40. Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH (2007) CD13/APN regulates endothelial invasion and filopodia formation. Blood 110(1):142-150
41. Risau W (1997) Mechanisms of angiogenesis. Nature 386(6626):671-674
42. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A (2004) Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64(19):7150-7155
43. Studier FW (2005) Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41(1):207-234
44. Tung CH (2004) Fluorescent peptide probes for in vivo diagnostic imaging. Biopolymers 76(5):391-403
45. Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, Weissleder R (2004) In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res 64(5):1579-1583
46. von Wallbrunn A, Waldeck J, Holtke C, Zuhlsdorf M, Mesters R, Heindel W, Schafers M, Bremer C (2008) In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt 13(1):011007
47. Weissleder R (2006) Molecular imaging in cancer. Science 312(5777):1168-1171
48. Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219(2):316-333
49. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17(4):375-378
50. Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14(9):823-833
51. Xiao Q, Hsu CY, Chen H, Ma X, Xu J, Lee JM (2005) Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388(Pt 3):913-920
52. Xing Y, Zhao J, Conti PS, Chen K (2014) Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics 4(3):290-306
53. Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89(12):1161-1167
54. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL (1999a) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13(1):181-189
55. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY (1999b) Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82(1):131-136
56. Zhang Z, Harada H, Tanabe K, Hatta H, Hiraoka M, Nishimoto S (2005) Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging. Peptides 26(11):2182-2187
57. Zhang N, Sanders AJ, Ye L, Jiang WG (2009a) Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med 24(1):3-8
58. Zhang N, Sanders AJ, Ye L, Kynaston HG, Jiang WG (2009b) Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro. Int J Oncol 35(6):1473-1480
59. Zhang N, Sanders AJ, Ye L, Kynaston HG, Jiang WG (2010) Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 30(1):87-95
60. Zhang S, Shao P, Bai M (2013) In vivo type 2 cannabinoid receptor-targeted tumor optical imaging using a near infrared fluorescent probe. Bioconjugate Chem 24(11):1907-1916